Interested in becoming an ACAAI member? Learn more about the benefits of membership and find your place in the College.

ACAAI 2023 ANNUAL SCIENTIFIC MEETING


PODIUM to PRACTICE ®
Embracing the Evolution of Patient Care
November 9-13, 2023


Submission Deadline: October 15, 2023 - 5:00 PM CDT - No extensions will be granted.


The College invites you to submit a Late-breaking abstract for the 2023 Annual Scientific Meeting, November 9 - 13, 2023. The theme of the meeting is: Embracing the Evolution of Patient Care.

Late-Breaking Abstract Submissions

  • A Presenting Author must be identified during the submission process for the abstract to be considered.
  • There will be a VERY LIMITED number of late-breaking abstracts accepted.
  • Late breaking abstracts must have completed data for review.
  • Late breaking abstract submissions must include a designated Presenting Author.
  • If you submit an abstract as a late-breaking abstract and it is not accepted, it will NOT be considered for acceptance in any other category, and will not be presented during the ACAAI 2023 Annual Meeting.
  • Case reports and limited clinical case series without novel research interventions will not be accepted in this category.
  • Upon submission, the Submitter will be required to attest that it was not possible to submit by the Research abstract deadline of July 10th due to the late breaking nature of data included within the abstract submission.
  • Late breaking abstracts will be reviewed by a select group from the Abstract Review Committee due to the rapid turnaround time for review.
  • Abstracts will be presented as featured abstracts in a separate session within the Exhibit Hall.
  • Accepted late breaking abstracts will appear in the online Annals of Allergy, Asthma and Immunology. Due to time constraints, accepted late breaking abstracts will not be published in the print version of the Annals.
  • Late-breaking Abstracts will be embargoed until November 9th - 8:00 am (PT). 
  • The Late-breaking Abstract Submission Center will close on October 15th at 5:00 pm Central.
  • **No requests for extensions will be granted.**


All accepted Abstracts will be published online as they appear within the ACAAI System as of the deadline date. No changes can be made after the close of the submission period.

Submission Information for Authors. Abstracts must be submitted electronically via the online form, and they must be complete, including the author listing. An unlimited number of Authors will be allowed in this category. ACAAI will not accept any abstracts or abstract changes after the submission deadline.

Submission Fee. There is a $250 non-refundable fee for each abstract submission. Payment does not guarantee that the abstract will be accepted. Payment must be made by credit card (Visa, MasterCard or American Express). Purchase orders and checks will not be accepted.

NOTE: All correspondence regarding the abstract submission will be sent to the submitter at the email address provided at time of submission. It is the responsibility of the submitter to ensure that all information is correct and approved by the participating authors.


Authorship. The College follows the ICMJE quidelines. The ICMJE recommends that authorship be based on the following 4 criteria:

  • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  • Drafting the work or revising it critically for important intellectual content; AND
  • Final approval of the version to be published; AND
  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved


Commercial Bias. All abstracts must be devoid of commercial bias. Trade names should not be used in referencing drugs, devices or instrumentation. Any medications or other substances referred to in the presentation material should be identified by their generic name or description. Trade name violations/commercial bias will result in below average scores or rejection. Failure to disclose *financial relationships with ACCME-defined **Ineligible Companies will prohibit an author/presenter from participating in oral and poster sessions.


Employees of pharmaceutical or medical device companies or other ACCME-defined **Ineligible Companies are prohibited from participating as an author or presenter of an oral abstract chosen for presentation during a CME Session; however, they may participate as an author or presenter for an electronic poster session, or an abstract chosen for oral presentation during a non-CME Distinguished Industry Oral Abstracts session.

*Financial relationships: Examples of financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed; diversified mutual funds do not need to be disclosed. Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individual’s institution receives the research grant and manages the funds.


**The ACCME defines an Ineligible Company as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies. Examples of ineligible companies include: • Advertising, marketing, or communication firms whose clients are ineligible companies • Bio-medical startups that have begun a governmental regulatory approval process • Compounding pharmacies that manufacture proprietary compounds • Device manufacturers or distributors; diagnostic labs that sell proprietary products • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements • Manufacturers of health-related wearable products • Pharmaceutical companies or distributors • Pharmacy benefit managers • Reagent manufacturers or sellers


All authors must complete the online Disclosure of Financial Relationships with Ineligible Companies by October 15, 2023 at 5:00 PM Central for Late-Breaking Abstracts
. Failure to comply with this requirement will result in the author being removed from the abstract.


Abstract Presentations. ACAAI only accepts original abstracts. Abstracts previously accepted and/or published by other organizations should not be submitted. If an abstract submitted to ACAAI Annual Meeting is accepted for programming and/or publication by another organization prior to its acceptance by ACAAI, it must be withdrawn from consideration for the ACAAI Annual Meeting.

We will not make the assumption that the submitting author is the presenting author. If you are the submitting author and the presenting author, you must list your name in the author listing and select the role of "Presenting Author." abstract. If submitting more than one abstract, you may identify a co-author as the presenter for other abstracts. An individual can only be the presenting author on one abstract.

As the submitting author, you are the main contact person for the abstract, and as such, it is your responsibility to make sure the other authors are informed of any communications from ACAAI regarding the abstract (including requests from the Abstract Review Subcommittee for additional information, disposition and placement decision, missing disclosures, etc). If you are unwilling or unable to function in this capacity, please designate an alternate contact person.

It is the responsibility of the submitting author to ensure accuracy of content, spelling and author information, including author listing order. Abstracts are directly exported from the submission database for publication.

Please review your submission carefully to make sure that all appropriate data and all authors are listed and in the correct order. Absolutely no changes will be accepted after the October 15, 2023, 5:00 pm (CDT) deadline.

Abstract Withdrawal. A written request must be submitted to education@acaai.org by October 15, 2023 at 5:00 pm Central. Any abstract withdrawn after that date cannot be guaranteed removal from any online or print promotional materials or publication.


Required Information Needed for Each Author. You must list your authors in the order in which they should appear in the abstract.

First Name, Middle Initial and Last Name

Credentials

Company/Institution Name

City, State and Country (where employed)

Author Email

A "Presenting Author" must be identified within the submission system by the October 15, 2023 deadline date for the abstract to be considered.

All authors listed on your abstract will receive an email with a link for completing their disclosure. Please make sure they respond. All authors are REQUIRED to disclose and it will be your responsibility as the Submitter and/or Presenting Author to follow-up with the authors to make sure the disclosures have been submitted.

Any author who has not completed the online disclosure by the October 15, 2023 deadline, will be removed from the abstract.

Note: If an author has previously completed a disclosure with ACAAI for the 2023 year, the completed disclosure will be applied to all abstracts where the author is listed.


Organization of Abstract Body

Abstract Length. There is a limit of 15 words for the title and 250 words for the body of your abstract submission.

Each abstract should be formatted as shown below (including the words "Introduction", "Methods", "Results" and "Conclusion" within your abstract submission:

Introduction: A brief introduction indicating the reason for the study

Methods: A description of the methods used to evaluate the study (do not include laboratory techniques)

Results: Specific data necessary to evaluate the abstract (Statements such as “data will be discussed at the presentation” are grounds for refusal of the abstract)

Conclusion: A brief conclusion indicating the significance of the results in terms of what was originally designed. The results should occupy 1/2 to 2/3 of the abstract. DO NOT mention the institution where the work was performed in the body or title of the abstract.

Be sure to use the words “Introduction, Methods, Results, Conclusion” in the body of your abstract to indicate the start of each new section. The abstract title and author information should not be included in the body of the abstract.

Best Results. Best results are achieved by typing directly into the online platform. Please make sure that you use the "Insert Symbols" feature in Word for any mathematical, Latin or scientific expressions. If you are entering the copy directly onto the Abstract Form, you must use the “Symbols” icon to ensure your results are displayed accurately. Always verify that your information is correct prior to submitting by selecting "Print Preview."


Title Guidelines. Do not use formatting tags in the title. The title will be formatted automatically by the system.. Abbreviations must not be used in the title. Check to ensure that you have not exceeded the character count limit.

Reproduced Materials - When previously published figures or tables are used, the author must obtain written permission from the copyright holder (usually the publisher) to reproduce the material. An appropriate credit line should be included in the figure legend or table footnote, and full publication information should be cited in the reference list. Letters of permission must accompany the manuscript at the time of submission.


Use of Figures. You may add one figure to your abstract, however, it is recommended that results be shown in narrative form, since figure formats may be compromised in publication. The figure must be submitted as a jpg file and cannot exceed 500kb.


Abstract Acceptance. If the abstract is accepted for presentation at the 2023 ACAAI Annual Meeting, the submitting author will be notified via email in late-October. Only the Submitter will be notified of the abstract disposition. Please make sure that your contact information is accurate. The notification will include: 1) placement decision and date and time of session. Accepted late-breaking Abstracts will be featured as in-person, Oral Presentations in a separate session within the Exhbit Hall. The decision of the ACAAI Abstract Review Subcommittee regarding acceptance and presentation of abstracts is final.

Meeting Registration. All authors who will be attending the Annual Meeting must register online for the meeting and pay any applicable registration fees. 

Back to Top